937602-40-9

Usage

Uses

Used in Organic Synthesis:
Pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride is utilized as a reagent in organic synthesis, specifically for the preparation of pyrazolo[1,5-a]pyrimidine derivatives and related compounds. Its ability to undergo nucleophilic substitution reactions is particularly valuable for introducing the carbonyl chloride group into a variety of organic molecules.
Used in Pharmaceutical Development:
In the pharmaceutical industry, Pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride is studied for its potential applications in the development of new drugs. Its unique structure and reactivity make it a candidate for targeting various biological pathways, which could lead to the creation of innovative treatments for different diseases.
It is crucial to handle Pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride with care due to the high reactivity and corrosive nature of carbonyl chlorides, ensuring safety in both research and industrial applications.

Upstream product

• 25940-35-6 pyrazolo[1,5-a] pyrimidine-3-carboxylic acid 
• 115932-00-8 pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester 

Downstream Products

• 1204925-53-0 3-[((2S)-2-Methyl-4-{[4-(trifluoromethyl)phenyl]sulfonyl}-1-piperazinyl)carbonyl]pyrazolo[1,5-a]pyrimidine 
• 310448-53-4 C₁₃H₉ClN₄O 
• 1401219-51-9 N-(3-(3,4-dimethoxyphenyl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401219-43-9 N-(3-(pyridin-4-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401219-47-3 N-(3-(2-methoxypyridin-4-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401219-42-8 N-(3-(6-methoxypyridin-3-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401219-48-4 N-(3-cyclopropyl-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401218-62-9 N-(3-(tetrahydro-2H-pyran-4-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401222-25-0 tert-butyl 4-(5-(pyrazolo[1,5-a]pyrimidine-3-carboxamido)-1-(p-tolyl)-1H-pyrazol-3-yl)piperidine-1-carboxylate 
• 1401219-49-5 N-(3-(4-methoxyphenyl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401218-52-7 N-(3-(1-methylpiperidin-4-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401218-53-8 N-(3-(1-isopropylpiperidin-4-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401218-47-0 N-(3-(1-acetylpiperidin-4-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1401218-51-6 N-(3-(1-carbamoylpiperidin-4-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant academic research and scientific papers

Efficient, Protecting Group Free Kilogram-Scale Synthesis of the JAK1 Inhibitor GDC-4379

The development of an improved kilogram-scale synthesis of the JAK1 inhibitorGDC-4379for the treatment of asthma is described. The new process is highlighted by a step-economical construction of a 3-substituted-4-aminopyrazole employing a telescoped oximation and hydrazine condensation of a 1,3-dielectrophile to generate nitrosopyrazole and a novel copper-catalyzed NaBH4reduction of the nitroso group. The endgame process features an amidation of aminopyrazole with acid chloride under Schotten-Baumann conditions to provide access to the penultimate intermediate. A selective N-1 alkylation of the pyrazole moiety was accomplished under phase-transfer conditions, which deliveredGDC-4379with a defined particle-size distribution suitable for micronization after recrystallization and wet milling.

Compound containing 2,4 - thiazole ring and preparation method and application thereof

The invention provides a compound containing 2,4 - thiazole rings and a preparation method and application thereof, wherein the compound is shown in a formula X. A Is pyrazolopyrimidine or indole. Z Is carbonless. X Is O or S. Y Is - O - or - NH . R1 Hydrogen or C1 -6 Alkyl. R2 Be selected from C1 - C3 Alkyl. C5 - C15 Alkenyl, alkynyl, 5 - RMB 10 heterocyclic radicals, C6 - C12 Aryl, 5 -12 membered heteroaryl, sterol and 5-10 元 cycloalkyl. Y And R2 Connection, or Y and R2 Looping. R3 From hydrogen. Halogen, amino, hydroxyl, acetyl, 3 - RMB 10 heterocyclic group, C6 - C12 Aryl, 5 -12-membered heteroaryl, 3 -10-membered cycloalkyl, ester, carboxy, trihalomethyl and adamantyl. R2 Or R3 It is unsubstituted or is selected from C. 1 - C6 Alkyl. A hydroxy group, a halogen group, a trihalomethyl group, a carboxyl group, and a phenyl group. R2 Document C1 - C3 Alkyl, R3 Hydrogen.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC50’s in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES

The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (0), Formula (I), and Formula (II) and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to carboxamide inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation

IRAK4 is a critical upstream kinase in the IL-1R/TLR signaling pathway. Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders. A screening campaign identified a pyrazole class of IRAK4 inhibitors that were d